SCHEMBL23847532

SCHEMBL23847532

CN1CCN(C2CCC(n3nc(I)c4c(N)ncnc43)CC2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 12/20 0.67
SRC P12931 12/20 0.67
KDR P35968 6/20 0.67
JAK2 O60674 2/20 0.67
PLK4 O00444 2/20 0.67
PRKD3 O94806 2/20 0.67
MAP4K4 O95819 2/20 0.67
NTRK1 P04629 2/20 0.67
INSR P06213 2/20 0.67
FYN P06241 2/20 0.67
RET P07949 2/20 0.67
ROS1 P08922 2/20 0.67
FER P16591 2/20 0.67
RPS6KB1 P23443 2/20 0.67
MARK3 P27448 2/20 0.67
AXL P30530 2/20 0.67
FLT4 P35916 2/20 0.67
CSNK1A1 P48729 2/20 0.67
CSNK1D P48730 2/20 0.67
BLK P51451 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL760441 1.00 LCK (0.67) LCKSRCKDRJAK2PLK4
SCHEMBL2960034 1.00 LCK (0.67) LCKSRCKDRJAK2PLK4
SCHEMBL760440 1.00 LCK (0.67) LCKSRCKDRJAK2PLK4
SCHEMBL31612025 0.93 LCK (0.64) LCKSRCKDRJAK2PLK4
SCHEMBL5812789 0.93 LCK (0.64) LCKSRCKDRJAK2PLK4
SCHEMBL4825086 0.90 LCK (0.70) LCKSRCKDRJAK2PLK4
SCHEMBL4828169 0.88 LCK (0.61) LCKSRCKDRJAK2PLK4
SCHEMBL4828163 0.88 LCK (0.61) LCKSRCKDRJAK2PLK4
SCHEMBL24096480 0.87 JAK2 (0.86) LCKSRCKDRJAK2PLK4
SCHEMBL29999054 0.87 JAK2 (0.86) LCKSRCKDRJAK2PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021188417-A1 COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA FLASH THERAPEUTICS, LLC (US) 2021-09-23 WO disclosed
US-RE48175-E1 Hydrophobically tagged small molecules as inducers of protein degradation DANA-FARBER CANCER INSTITUTE, INC. (US) 2020-08-25 US disclosed
US-20180093990-A1 HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-04-05 US disclosed
US-20180093990-A1 HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-04-05 US disclosed
US-9758522-B2 Hydrophobically tagged small molecules as inducers of protein degradation DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-09-12 US disclosed
US-9758522-B2 Hydrophobically tagged small molecules as inducers of protein degradation DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-09-12 US disclosed
US-20150274738-A1 HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION Dana-Farber Cancer, Institute, Inc. (US) 2015-10-01 US disclosed
US-20150274738-A1 HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION Dana-Farber Cancer, Institute, Inc. (US) 2015-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274738-A1 HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION MYC, TP53, MDM2 LCK 401/4885SRC 322/4885KDR 1084/4885
US-20180093990-A1 HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION MYC, TP53, MDM2 LCK 401/4885SRC 322/4885KDR 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.